SCIENTIFIC BACKGROUND

AKT1, ALK, BRAF, CTNNB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, MYC, NF1, NRAS, NTRK1, NTRK2, NTRK3, PIK3CA, POLE, PTEN, RET, ROS1, TP53

Category:

Scientific Background

The ForeSENTIA Melanoma panel tests for single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 22 genes which are commonly found in melanomas. Melanoma is a malignant type of skin cancer that arises from cells in the skin, the melanocytes. It is the 17th most common type of cancer worldwide and in 2020 there were more than 300,000 new cases diagnosed with melanoma. Factors such as environmental and inheritance can increase the risk of developing melanoma. Accumulation of genetic alterations (mutations) in the DNA can result in melanoma initiation and development. Mutations in genes including BRAF, NRAS, and others, are frequently found in patients with melanoma. Identification of mutations can have huge potential and can provide the necessary information about the genetic characteristics of the tumor, therefore having a prognostic and therapeutic value. Personalized medicine tailored to each patient can be beneficial for increasing the chances of melanoma treatment depending on the unique mutations in each cancer patient. Indeed, over the last decade novel personalized therapeutic opportunities have been developed and currently, there are different FDA/EMA-approved drugs for melanoma, including vemurafenib.

 

This panel can optionally test for Microsatellite Instability (MSI) immunotherapy biomarker. Studies show that MSI is frequently found in melanoma patients and can be a predictive factor for identifying patients who might respond to immunotherapy. The FDA-approved drug pembrolizumab can be used as an immunotherapy option for melanoma patients with MSI-high status.

 

Recommendations by professional bodies:

“Mutation testing for actionable mutations is mandatory in patients with resectable or unresectable stage III or stage IV and is highly recommended in high-risk resected disease stage IIC but not for stage I or stage IIA–IIB [I, A]. BRAF testing is mandatory [I, A]” (Michielin et al., 2019).

 

References and more information: 

Information obtained from professional bodies including National Cancer Institute, and World Cancer Research Fund International

Kubeček O, Kopecký J. Microsatellite instability in melanoma: a comprehensive review. Melanoma Res. 2016 Dec;26(6):545-550. doi: 10.1097/CMR.0000000000000298. PMID: 27623135.

Alvino E, Passarelli F, Cannavò E, Fortes C, Mastroeni S, Caporali S, Jiricny J, Cappellini GC, Scoppola A, Marchetti P, Modesti A, D'Atri S. High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma. Am J Clin Pathol. 2014 Jul;142(1):121-32. doi: 10.1309/AJCPCX2D9YULBBLG. PMID: 24926095.

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Dec 1;30(12):1884-1901. doi: 10.1093/annonc/mdz411. PMID: 31566661.

GENES

AKT1, ALK, BRAF, CTNNB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, MYC, NF1, NRAS, NTRK1, NTRK2, NTRK3, PIK3CA, POLE, PTEN, RET, ROS1, TP53
How to order

LATEST ARTICLES

Cystic fibrosis (CF) is a life-threatening, progressive, inherited condition that causes severe damage to the body, primarily affecting the organs of...

Read more

Down syndrome is a genetic condition caused by the presence of an extra copy of chromosome 21. It affects physical growth, facial features, and cogni...

Read more

Every year on April 25th, DNA Day celebrates the discovery of DNA’s double helix and the advances we’ve made in understanding genetics. D...

Read more

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more